{"id":"coronavac-coronavac","safety":{"commonSideEffects":[{"rate":"20-40","effect":"Injection site pain or swelling"},{"rate":"10-30","effect":"Fatigue"},{"rate":"10-25","effect":"Headache"},{"rate":"10-20","effect":"Myalgia"},{"rate":"5-15","effect":"Fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CoronaVac uses chemically inactivated whole SARS-CoV-2 virions to trigger both humoral (antibody) and cell-mediated immune responses. The inactivated virus particles are unable to replicate but retain antigenic epitopes that train the adaptive immune system to recognize and neutralize live virus upon exposure. This approach has been used successfully for decades in vaccines against other viral pathogens such as polio and influenza.","oneSentence":"CoronaVac is an inactivated SARS-CoV-2 vaccine that stimulates the immune system to produce antibodies and cellular immunity against the virus.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:45:23.397Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of COVID-19 in adults and adolescents"}]},"trialDetails":[{"nctId":"NCT07408297","phase":"PHASE2","title":"Evaluating Safety and Immune Response of Janssen, Moderna, Pfizer/BNT, and Novavax COVID-19 Vaccines for Same and Mixed Boosters in Adolescents and Adults Aged 12-64 With and Without HIV in Kenya, DRC, and Rwanda","status":"COMPLETED","sponsor":"Victoria Biomedical Research Institute","startDate":"2022-05-18","conditions":"COVID -19, SARS CoV 2 Infection","enrollment":1919},{"nctId":"NCT05904054","phase":"PHASE2","title":"Immunogenicity and Safety Study of SARS-CoV-2 DNA Vaccine (ICCOV)","status":"COMPLETED","sponsor":"Immuno Cure 3 Limited","startDate":"2023-06-15","conditions":"COVID-19","enrollment":31},{"nctId":"NCT05303584","phase":"PHASE4","title":"Heterologous Boost Immunization with Ad5-nCoV After Three-dose Priming with an Inactivated SARS-CoV-2 Vaccine","status":"COMPLETED","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2022-04-23","conditions":"COVID-19","enrollment":362},{"nctId":"NCT05599555","phase":"","title":"Community-based Sero-epidemiological Study of COVID-19","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2022-04-28","conditions":"COVID-19","enrollment":9600},{"nctId":"NCT05697705","phase":"","title":"Effectiveness of the Oxford-AstraZeneca COVID-19 Vaccine as a 2nd Booster, the REFORCO-Brazil Study","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-07-22","conditions":"COVID-19","enrollment":188814085},{"nctId":"NCT05501522","phase":"PHASE3","title":"Immunogenicity and Safety Study of Heterologous Booster Vaccination of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine(GBP510) Adjuvanted with AS03 in Adults Aged 18 Years and Older","status":"COMPLETED","sponsor":"SK Bioscience Co., Ltd.","startDate":"2022-12-09","conditions":"COVID-19","enrollment":840},{"nctId":"NCT06597370","phase":"","title":"Immunogenicity Induced by COVID-19 Vaccines in Mexican Population","status":"COMPLETED","sponsor":"National Polytechnic Institute, Mexico","startDate":"2021-09-01","conditions":"COVID-19 Vaccine","enrollment":80},{"nctId":"NCT04611243","phase":"","title":"Lung Function, Exercise Capacity, and Serology Responses in Patients With COVID-19","status":"RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2020-05-22","conditions":"Lung Function, Exercise Capacity, Quality of Life","enrollment":700},{"nctId":"NCT05381350","phase":"PHASE3","title":"Immunogenicity and Safety of Booster Immunization of COVID-19 Vaccine (Vero Cell), Inactivated (Omicron Variant) in Healthy People Aged 18 Years and Above","status":"COMPLETED","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2022-06-01","conditions":"COVID-19","enrollment":1750},{"nctId":"NCT05230940","phase":"PHASE2","title":"Efficacy, Immunogenicity, and Safety of TURKOVAC Vaccine Versus the CoronaVac Vaccine Against COVID-19 in Healthy Adolescent","status":"COMPLETED","sponsor":"Health Institutes of Turkey","startDate":"2022-02-18","conditions":"COVID-19, Sars-CoV-2 Infection","enrollment":1},{"nctId":"NCT04582344","phase":"PHASE3","title":"Clinical Trial For SARS-CoV-2 Vaccine (COVID-19)","status":"COMPLETED","sponsor":"Health Institutes of Turkey","startDate":"2020-09-14","conditions":"COVID-19","enrollment":10214},{"nctId":"NCT05863429","phase":"","title":"Observational National Vaccine Study","status":"COMPLETED","sponsor":"Health Institutes of Turkey","startDate":"2022-05-18","conditions":"COVID-19 Infection","enrollment":200},{"nctId":"NCT04754698","phase":"PHASE4","title":"COVID-19 CoronaVac in Patients With Autoimmune Rheumatic Diseases and HIV/AIDS","status":"COMPLETED","sponsor":"University of Sao Paulo General Hospital","startDate":"2021-02-09","conditions":"Rheumatic Disease, HIV Infections, AIDS","enrollment":2196},{"nctId":"NCT05897190","phase":"PHASE1","title":"Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Vaccine Booster","status":"COMPLETED","sponsor":"Argorna Pharmaceuticals Co., LTD","startDate":"2022-05-16","conditions":"SARS-CoV-2","enrollment":60},{"nctId":"NCT05387317","phase":"PHASE3","title":"Evaluation of COVID-19 Vaccines Given as a Booster in Healthy Adults in Indonesia (MIACoV Indonesia)","status":"WITHDRAWN","sponsor":"Murdoch Childrens Research Institute","startDate":"2024-04","conditions":"COVID-19","enrollment":""},{"nctId":"NCT04942405","phase":"PHASE3","title":"Efficacy, Immunogenicity, and Safety of the Inactivated COVID-19 Vaccine (TURKOVAC) Versus the CoronaVac Vaccine","status":"COMPLETED","sponsor":"Health Institutes of Turkey","startDate":"2021-06-21","conditions":"Covid19","enrollment":1290},{"nctId":"NCT05077176","phase":"PHASE3","title":"Phase 3 Booster Vaccination Against COVID-19","status":"COMPLETED","sponsor":"Health Institutes of Turkey","startDate":"2021-10-08","conditions":"COVID-19, Sars-CoV-2 Infection","enrollment":4340},{"nctId":"NCT05104385","phase":"","title":"Hacettepe University COVID-19 Vaccinated's Health Cohort- Students of Health Sciences","status":"COMPLETED","sponsor":"Hacettepe University","startDate":"2021-06-21","conditions":"COVID-19 Pandemic, SARS-CoV2 Infection, Immunization; Infection","enrollment":1223},{"nctId":"NCT04898946","phase":"","title":"Serological Response to mRNA and Inactivated COVID-19 Vaccine in Health Care Workers in Hong Kong","status":"COMPLETED","sponsor":"Hong Kong Sanatorium & Hospital","startDate":"2021-03-07","conditions":"Covid-19 Vaccine","enrollment":480},{"nctId":"NCT04456595","phase":"PHASE3","title":"Clinical Trial of Efficacy and Safety of Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine in Healthcare Professionals","status":"COMPLETED","sponsor":"Butantan Institute","startDate":"2020-07-21","conditions":"COVID-19","enrollment":12688},{"nctId":"NCT04747821","phase":"PHASE4","title":"An Effectiveness Study of the Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine","status":"COMPLETED","sponsor":"Butantan Institute","startDate":"2021-02-07","conditions":"Covid19","enrollment":27711},{"nctId":"NCT05593042","phase":"PHASE2","title":"Immunogenicity Evaluation of Omicron Variant-based Vaccine and a Trivalent Vaccine in Adults Against COVID-19 in Chile","status":"COMPLETED","sponsor":"Pontificia Universidad Catolica de Chile","startDate":"2022-11-28","conditions":"COVID-19, Vaccines","enrollment":551},{"nctId":"NCT04832932","phase":"","title":"The COVID-19 Back-to-Normal Study: Analysis of Multiple Outcomes","status":"UNKNOWN","sponsor":"Mebo Research, Inc.","startDate":"2021-01-05","conditions":"COVID-19 Vaccines","enrollment":2000},{"nctId":"NCT04800133","phase":"PHASE2","title":"Covid-19 Vaccination in Adolescents and Children","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2021-05-08","conditions":"Covid19","enrollment":1018},{"nctId":"NCT05057169","phase":"PHASE4","title":"Randomized Trial of COVID-19 Booster Vaccinations (Cobovax Study)","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2021-11-18","conditions":"COVID-19 Vaccination","enrollment":400},{"nctId":"NCT04979949","phase":"PHASE2","title":"Booster Vaccination Against COVID-19","status":"COMPLETED","sponsor":"Health Institutes of Turkey","startDate":"2021-07-12","conditions":"COVID-19, Sars-CoV-2 Infection","enrollment":222},{"nctId":"NCT05052307","phase":"","title":"A Real-world Evidence Study of BNT162b2 mRNA Covid-19 Vaccine in Brazil","status":"COMPLETED","sponsor":"Hospital Moinhos de Vento","startDate":"2021-11-03","conditions":"Covid19","enrollment":4574},{"nctId":"NCT05112913","phase":"PHASE4","title":"Lot-to-lot Consistency of an Inactivated SARS-CoV-2 Vaccine Between Different Workshops in Healthy Children Aged 3-17 Years","status":"UNKNOWN","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2021-07-27","conditions":"COVID-19","enrollment":2520},{"nctId":"NCT05329038","phase":"PHASE4","title":"Immunogenicity，Safety and Cross - Immune Response With Mutant Strains of a Third Dose of an Inactivated COVID-19 Vaccine","status":"UNKNOWN","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2022-04-19","conditions":"COVID-19","enrollment":180},{"nctId":"NCT05403307","phase":"","title":"A Real-world Evidence Study of BNT162b2 mRNA Covid-19 Vaccine Among Children in Brazil","status":"COMPLETED","sponsor":"Hospital Moinhos de Vento","startDate":"2022-06-08","conditions":"COVID-19","enrollment":757},{"nctId":"NCT05137418","phase":"PHASE3","title":"Safety and Immunogenicity of COVID-19 Vaccine, Inactivated in Healthy Population Aged From 3 to 11 Years","status":"COMPLETED","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2021-11-27","conditions":"COVID-19","enrollment":1000},{"nctId":"NCT04992260","phase":"PHASE3","title":"Efficacy, Immunogenicity and Safety of COVID-19 Vaccine , Inactivated in Children and Adolescents","status":"COMPLETED","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2021-09-10","conditions":"COVID-19","enrollment":11349},{"nctId":"NCT05788185","phase":"PHASE1, PHASE2","title":"Safety & Immunogenicity of RVM-V001/RVM-V002 or RVMV001+RVMV002 (Co Administered as Separate Injections) in Healthy Individuals","status":"TERMINATED","sponsor":"RVAC Medicines (US), Inc.","startDate":"2023-03-22","conditions":"Infectious Disease, COVID-19","enrollment":24},{"nctId":"NCT04775069","phase":"PHASE4","title":"Antibody Response to COVID-19 Vaccines in Liver Disease Patients","status":"COMPLETED","sponsor":"Humanity & Health Medical Group Limited","startDate":"2021-05-21","conditions":"Chronic Liver Disease","enrollment":232},{"nctId":"NCT04911790","phase":"PHASE4","title":"Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Adults","status":"COMPLETED","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2021-06-05","conditions":"COVID-19","enrollment":131650},{"nctId":"NCT05198336","phase":"PHASE4","title":"Immunogenicity of an Inactivated COVID-19 Vaccine","status":"COMPLETED","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2022-01-08","conditions":"COVID-19","enrollment":395},{"nctId":"NCT04992208","phase":"PHASE4","title":"Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Children and Adolescents","status":"COMPLETED","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2021-07-24","conditions":"COVID-19","enrollment":31041},{"nctId":"NCT05254236","phase":"PHASE2","title":"Immunogenicity and Safety Study of the 3rd Booster Dose Using the High or Medium Dose of Inactivated Vaccine in Healthy Adults in in Hong Kong","status":"WITHDRAWN","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2022-02-10","conditions":"COVID-19","enrollment":""},{"nctId":"NCT05411471","phase":"PHASE2","title":"Immunogenicity and Safety Study of Booster Vaccine With the COVID-19 Vaccine (Vero Cell), Inactivated, Omicron Strain","status":"COMPLETED","sponsor":"Sinovac Biotech (Hong Kong) Limited","startDate":"2022-06-08","conditions":"COVID-19","enrollment":221},{"nctId":"NCT04884685","phase":"PHASE2","title":"Safety of an Inactivated SARS-CoV-2 Vaccine (CoronaVac) in Children and Adolescents","status":"COMPLETED","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2021-05-03","conditions":"COVID-19","enrollment":500},{"nctId":"NCT05205096","phase":"PHASE1, PHASE2","title":"Immunogenicity and Safety of Booster Immunization of ZF2001 After Inoculation With Two Doses of CoronaVac","status":"COMPLETED","sponsor":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","startDate":"2021-11-10","conditions":"COVID-19","enrollment":480},{"nctId":"NCT05188677","phase":"PHASE3","title":"Immunogenicity and Safety Study of SCB-2019 Vaccine as a Booster to COVID-19 Vaccine in Adults","status":"COMPLETED","sponsor":"Clover Biopharmaceuticals AUS Pty","startDate":"2022-06-13","conditions":"COVID-19","enrollment":1831},{"nctId":"NCT04993209","phase":"PHASE1","title":"Clinical Trial of the COVID-19 Vaccine (Recombinant, Inactivated) in Brazil","status":"COMPLETED","sponsor":"Butantan Institute","startDate":"2021-07-09","conditions":"Coronavirus Infections, Healthy","enrollment":320},{"nctId":"NCT05710289","phase":"","title":"A Blood Collection Study to Assess the Immunogenicity of Nationally Authorized Homologous COVID-19 Booster Vaccines Among Adult Vaccinees.","status":"WITHDRAWN","sponsor":"SK Bioscience Co., Ltd.","startDate":"2023-02","conditions":"COVID-19","enrollment":""},{"nctId":"NCT05928455","phase":"EARLY_PHASE1","title":"The Immunogenicity and Safety Following a Heterologous Booster Dose of Recombinant SARS-CoV-2 Vaccine LYB001","status":"UNKNOWN","sponsor":"Guangzhou Patronus Biotech Co., Ltd.","startDate":"2022-05-14","conditions":"COVID-19, Vaccine Reaction","enrollment":120},{"nctId":"NCT05918939","phase":"EARLY_PHASE1","title":"UNAIR Inactivated COVID-19 Vaccine as Heterologue Booster (Immunobridging Study)","status":"UNKNOWN","sponsor":"Dr. Soetomo General Hospital","startDate":"2022-09-05","conditions":"COVID-19 Pandemic, COVID-19 Vaccines","enrollment":350},{"nctId":"NCT05226429","phase":"PHASE1, PHASE2","title":"UNAIR Inactivated COVID-19 Vaccine","status":"UNKNOWN","sponsor":"Dr. Soetomo General Hospital","startDate":"2022-02-08","conditions":"COVID-19 Pandemic, Vaccine Reaction","enrollment":495},{"nctId":"NCT05169008","phase":"PHASE3","title":"A Study to Evaluate the Safety and Immunogenicity of Ad5-nCoV and Ad5-nCoV-IH in CoronaVac Immunized Children and Adolescents","status":"TERMINATED","sponsor":"CanSino Biologics Inc.","startDate":"2022-02-25","conditions":"COVID-19","enrollment":91},{"nctId":"NCT05096832","phase":"PHASE3","title":"Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Booster Study","status":"COMPLETED","sponsor":"Livzon Pharmaceutical Group Inc.","startDate":"2021-11-03","conditions":"COVID-19 Pandemic","enrollment":10381},{"nctId":"NCT05228912","phase":"","title":"Immunization of 7 Different Vaccines Against SARS-COV-2 Across 4 Countries.","status":"COMPLETED","sponsor":"Hospital Clinica Nova","startDate":"2021-02-26","conditions":"Vaccine Adverse Reaction, COVID-19, Vaccine Reaction","enrollment":1870},{"nctId":"NCT05156632","phase":"PHASE3","title":"Efficacy,Immunogenicity and Safety of COVID-19 Vaccine , Inactivated Booster Dose in Adults Aged 18 Years and Above","status":"WITHDRAWN","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2023-02-20","conditions":"COVID-19","enrollment":""},{"nctId":"NCT05428592","phase":"PHASE3","title":"Clinical Trial of SARS-CoV-2 mRNA Vaccine(LVRNA009) as Heterologous Booster in Islamabad","status":"UNKNOWN","sponsor":"AIM Vaccine Co., Ltd.","startDate":"2023-04","conditions":"SARS-CoV-2","enrollment":1100},{"nctId":"NCT04651790","phase":"PHASE3","title":"Efficacy, Safety, and Immunogenicity of Two Vaccination Schedules of an Inactivated Vaccine Against COVID-19 in Adults","status":"COMPLETED","sponsor":"Pontificia Universidad Catolica de Chile","startDate":"2020-11-27","conditions":"Covid19, Vaccines","enrollment":2300},{"nctId":"NCT05683561","phase":"PHASE3","title":"A Phase III Clinical Trial to Evaluate the Efficacy and Safety of SCTV01E in Healthy People","status":"UNKNOWN","sponsor":"Sinocelltech Ltd.","startDate":"2023-01-25","conditions":"COVID-19 SARS-CoV-2 Infection","enrollment":6000},{"nctId":"NCT05367895","phase":"","title":"Effectiveness of Inactivated COVID-19 Vaccine of the First Booster Dose","status":"UNKNOWN","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2022-07-30","conditions":"COVID-19","enrollment":14000},{"nctId":"NCT05433272","phase":"PHASE3","title":"Immunogenicity and Safety Study of One Booster Dose of Trivalent COVID-19 Vaccine (Vero Cell), Inactivated","status":"UNKNOWN","sponsor":"Sinovac Biotech (Colombia) S.A.S.","startDate":"2023-08-10","conditions":"COVID-19","enrollment":1400},{"nctId":"NCT05668065","phase":"PHASE3","title":"Immunogenicity of Heterologous Versus Homologous Prime Boost Schedule With mRNA and Inactivated COVID-19 Vaccines","status":"COMPLETED","sponsor":"Institut Pasteur de Tunis","startDate":"2021-11-22","conditions":"COVID-19","enrollment":199},{"nctId":"NCT05583357","phase":"EARLY_PHASE1","title":"Exploratory Clinical Study to Evaluation of the Safety and Immunogenicity of Bivalent Vaccine V-01D-351","status":"UNKNOWN","sponsor":"Livzon Pharmaceutical Group Inc.","startDate":"2022-08-15","conditions":"COVID-19 Pandemic","enrollment":40},{"nctId":"NCT05508477","phase":"PHASE3","title":"UNAIR Inactivated COVID-19 Vaccine Phase III (Immunobridging Study)","status":"UNKNOWN","sponsor":"Dr. Soetomo General Hospital","startDate":"2022-06-28","conditions":"COVID-19 Pandemic, COVID-19 Vaccines","enrollment":4005},{"nctId":"NCT04974164","phase":"","title":"Effectiveness of COVID-19 Vaccine for Prevention of COVID-19 in the Dominican Republic","status":"COMPLETED","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2021-08-17","conditions":"COVID-19","enrollment":1400},{"nctId":"NCT04952727","phase":"PHASE4","title":"Study on Sequential Immunization of Inactivated COVID-19 Vaccine and Recombinant COVID-19 Vaccine (Ad5 Vector) in Elderly Adults","status":"COMPLETED","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2021-08-26","conditions":"COVID-19","enrollment":300},{"nctId":"NCT05148949","phase":"PHASE4","title":"Study on Three Doses of an Inactivated COVID-19 Vaccine in Chinese Pulmonary Tuberculosis Patients","status":"UNKNOWN","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2021-12-22","conditions":"COVID-19, Pulmonary Tuberculosis","enrollment":240},{"nctId":"NCT05165966","phase":"PHASE4","title":"Safety and Immunogenicity Study of Booster Vaccination in Different Doses of COVID-19 Vaccine (Vero Cell),Inactivated for Prevention of COVID-19","status":"COMPLETED","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2021-10-20","conditions":"COVID-19","enrollment":340},{"nctId":"NCT05398926","phase":"PHASE4","title":"Immunogenicity and Safety of a Third Dose of COVID-19 Vaccine(Vero Cell), Inactivated in the Elderly","status":"COMPLETED","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2021-12-06","conditions":"COVID-19","enrollment":400},{"nctId":"NCT05150496","phase":"PHASE2","title":"Immunogenicity and Safety Study of the 3rd Booster Dose Using the High or Medium Dose of Inactivated (CoronaVac®) Vaccine in Healthy Adults in Turkey","status":"SUSPENDED","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2022-12-15","conditions":"COVID-19","enrollment":640},{"nctId":"NCT05165732","phase":"PHASE4","title":"Safety and Immunogenicity Study of Booster Vaccination With COVID-19 Vaccine (Vero Cell),Inactivated From Different Manufactures for Prevention of COVID-19","status":"SUSPENDED","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2022-12-20","conditions":"COVID-19","enrollment":480},{"nctId":"NCT05216484","phase":"PHASE3","title":"Clinical Study of the Third Dose Immunization Schedule of COVID-19 Inactivated Vaccine, (Vero Cells) in Adults Aged 18 Years and Above (6 Months After Two Doses)","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2022-02-18","conditions":"SARS-CoV-2 Infection","enrollment":480},{"nctId":"NCT05029245","phase":"PHASE3","title":"IntraDermal Versus Intramuscular Comirnaty® Efficacy Study","status":"WITHDRAWN","sponsor":"Department of Medical Services Ministry of Public Health of Thailand","startDate":"2021-08-31","conditions":"Covid19 Vaccine, Covid19","enrollment":""},{"nctId":"NCT05289206","phase":"NA","title":"Immune Response of an Interchangeable Booster Vaccine Against COVID-19 Among Individuals With Risk Factors for Severity","status":"UNKNOWN","sponsor":"Fundação de Medicina Tropical Dr. Heitor Vieira Dourado","startDate":"2021-09-30","conditions":"Comorbidities and Coexisting Conditions, Healthy","enrollment":4446},{"nctId":"NCT05313074","phase":"NA","title":"SARS-CoV-2 Specific Immune Response After COVID-19 Vaccination in Cancer Patients","status":"COMPLETED","sponsor":"National Cancer Institute, Thailand","startDate":"2021-03-23","conditions":"COVID-19, Cancer","enrollment":311},{"nctId":"NCT04953325","phase":"PHASE4","title":"Immunogenicity and Safety of an Inactivated COVID-19 Vaccine","status":"COMPLETED","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2021-07-09","conditions":"COVID-19","enrollment":270},{"nctId":"NCT04894227","phase":"PHASE4","title":"Lot-to-lot Consistency of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Healthy Adults","status":"COMPLETED","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2021-05-11","conditions":"COVID-19","enrollment":1080},{"nctId":"NCT04834869","phase":"","title":"COVID-19 Vaccines Safety Tracking (CoVaST)","status":"RECRUITING","sponsor":"Masaryk University","startDate":"2021-04-01","conditions":"Adverse Reaction to Vaccine, COVID19 Vaccine","enrollment":30000},{"nctId":"NCT04892459","phase":"PHASE4","title":"Study on Sequential Immunization of Inactivated SARS-CoV-2 Vaccine and Recombinant SARS-CoV-2 Vaccine (Ad5 Vector)","status":"COMPLETED","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2021-05-25","conditions":"COVID-19","enrollment":300},{"nctId":"NCT04801667","phase":"PHASE4","title":"Evaluate the Impact, Safety, Tolerability and Immunogenicity of the Coronavac Vaccine in Kidney Transplant Recipients","status":"UNKNOWN","sponsor":"Hospital do Rim e Hipertensão","startDate":"2021-03-20","conditions":"SARS-CoV Infection, Coronavirus Infection, Vaccine Adverse Reaction","enrollment":3371},{"nctId":"NCT05079217","phase":"PHASE4","title":"Safety and Immunogenicity Study of Booster Vaccination With Medium-dosage or High-dosage SARS-CoV-2 Inactivated Vaccine for Prevention of COVID-19","status":"UNKNOWN","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2021-12-17","conditions":"COVID-19","enrollment":1200},{"nctId":"NCT05163652","phase":"PHASE3","title":"Clinical Study of the Third Dose Immunization Schedule of COVID-19 Inactivated Vaccine, (Vero Cells) Based on Different COVID-19 Inactivated Vaccine in Adults Aged 18 Years and Above","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2021-12-18","conditions":"SARS-CoV-2 Infection","enrollment":432},{"nctId":"NCT05225285","phase":"PHASE3","title":"Efficacy, Immunogenicity and Safety of Inactivated Vaccine (Coronavac) Against SARS-COV2 in Children and Adolescents","status":"UNKNOWN","sponsor":"Federal University of Espirito Santo","startDate":"2022-01-21","conditions":"COVID-19","enrollment":1120},{"nctId":"NCT05119738","phase":"","title":"Immune Response to Third Dose of SARS-CoV-2 Vaccine in a Cohort of Cancer Patients on Active Treatment","status":"UNKNOWN","sponsor":"Pontificia Universidad Catolica de Chile","startDate":"2021-10-27","conditions":"Sars-CoV-2 Infection","enrollment":122},{"nctId":"NCT05124509","phase":"","title":"Immune Response to Third Dose of COVID-19 Vaccine in Solid Organ Transplant","status":"COMPLETED","sponsor":"Pontificia Universidad Catolica de Chile","startDate":"2021-10-06","conditions":"COVID-19, SARS-CoV-2 Infection, Solid Organ Transplant","enrollment":147},{"nctId":"NCT05087368","phase":"PHASE2","title":"Immunogenicity and Safety of Heterologous and Homologous Boosting With ChAdOx1-S and CoronaVac or a Formulation of SCB-2019 (COVID-19)","status":"UNKNOWN","sponsor":"D'Or Institute for Research and Education","startDate":"2021-12-01","conditions":"Covid19","enrollment":520},{"nctId":"NCT04962308","phase":"PHASE4","title":"Clinical Trial of Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Healthy Adults","status":"UNKNOWN","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2021-06-19","conditions":"COVID-19","enrollment":1400},{"nctId":"NCT05026879","phase":"","title":"Adverse Events Report of Inactivated COVID-19 Vaccine","status":"COMPLETED","sponsor":"Bozyaka Training and Research Hospital","startDate":"2021-02-14","conditions":"COVID-19, Vaccine Adverse Reaction","enrollment":4040},{"nctId":"NCT04992182","phase":"PHASE2","title":"Reactogenicity, Safety, and Immunogenicity of Covid-19 Vaccine Booster","status":"UNKNOWN","sponsor":"Universidad del Desarrollo","startDate":"2021-07-08","conditions":"Covid19","enrollment":534},{"nctId":"NCT04789356","phase":"PHASE4","title":"Effectiveness of the Adsorbed Vaccine COVID-19 (Coronavac) Among Education and Public Safety Workers With Risk Factors for Severity","status":"UNKNOWN","sponsor":"Fundação de Medicina Tropical Dr. Heitor Vieira Dourado","startDate":"2021-03-18","conditions":"Covid19","enrollment":6233},{"nctId":"NCT04756830","phase":"PHASE4","title":"A Study to Assess the Safety and Immunogenicity of the Coronavac Vaccine Against COVID-19","status":"UNKNOWN","sponsor":"D'Or Institute for Research and Education","startDate":"2021-02-19","conditions":"COVID-19","enrollment":1200},{"nctId":"NCT04765215","phase":"","title":"Investigation of the Effectiveness of CoronaVac Vaccine in Cancer Patients With Active Chemotherapy and Comparison With Healthy People.","status":"UNKNOWN","sponsor":"Asoc. Prof. Erdoğan Selçuk Şeber","startDate":"2021-03-31","conditions":"Is the Coronovac Vaccine Effective in Patients Receiving Chemotherapy","enrollment":291},{"nctId":"NCT04854408","phase":"","title":"Evaluation of the Effect of Coronavac Vaccine (Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2 Vaccine) on Healthcare Workers' Menstrual Patterns","status":"COMPLETED","sponsor":"Kanuni Sultan Suleyman Training and Research Hospital","startDate":"2021-03-18","conditions":"Covid19, Vaccine Reaction, Coronavirus","enrollment":300},{"nctId":"NCT04751721","phase":"NA","title":"Oxidative Stress Parameters, Trace Element and Quality of Life in Women Before and After Covid-19 Vaccines","status":"UNKNOWN","sponsor":"Izmir Bakircay University","startDate":"2021-02","conditions":"Covid-19 Vaccine","enrollment":20},{"nctId":"NCT04751695","phase":"NA","title":"Oxidative Stress Parameters, Trace Element and Quality of Life in Men Before and After Covid-19 Vaccines","status":"UNKNOWN","sponsor":"Izmir Bakircay University","startDate":"2021-02","conditions":"Covid-19 Vaccine","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":11,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"CoronaVac/CoronaVac","genericName":"CoronaVac/CoronaVac","companyName":"Institut Pasteur de Tunis","companyId":"institut-pasteur-de-tunis","modality":"Biologic","firstApprovalDate":"","aiSummary":"CoronaVac is an inactivated SARS-CoV-2 vaccine that stimulates the immune system to produce antibodies and cellular immunity against the virus. Used for Prevention of COVID-19 in adults and adolescents.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}